

Curriculum Vitae
Clyde W. Yancy, M.D., F.A.C.C.

Place and Date of Birth:

Licensure: Texas -
 Louisiana -

Specialty Boards: Diplomate of the American Board of Internal Medicine, 9/85

Sub-Specialty Boards: Diplomate in the Sub-specialty of Cardiovascular Disease, 11/8/89

Current Position: Associate Professor of Medicine, Division of Cardiology
 Department of Internal Medicine
 University of Texas Southwestern Medical Center at Dallas
 Associate Dean of Clinical Affairs
 St. Paul University Hospital

Office Address: University of Texas Southwestern Medical Center
 Department of Internal Medicine
 Division of Cardiology, CS7.102
 5323 Harry Hines Blvd.
 Dallas, TX 75390-9047
 (214) 648-2444
 (214) 648-6783 (facsimile)
 Clyde.Yancy@UTSouthwestern.edu (e-mail)

Home Address:

Citizen Status:

Sex:

Marital Status:

Dependents:

###

CLINICAL HIGHLIGHTS

Medical Director, Heart Transplant Program, St. Paul Medical Center, Dallas, Texas.

- Consistent 90% one-year survival rate, 80% three-year survival rate; clinical outcomes among top 10% of heart transplant programs in the country; data are current through 2002.

Medical Director, Heart Transplant Program, Baylor University Medical Center, Dallas, Texas.

- Improved one-year survival from 78% to 92% from 1996-2002.

Medical Director, Cardiovascular Institute, St. Paul Medical Center, Dallas, Texas.

- Established successful heart failure management program with a less than 5% Medicare readmission rate and featuring a novel quarterly tutorial session, ongoing since 1st quarter '98.
- Over 200 health care professionals have been educated through 2002
- Established the only multidisciplinary pulmonary hypertension program in North Texas.

RESEARCH HIGHLIGHTS

(See Bibliography)

Skeletal muscle dysfunction and congestive heart failure

- Described altered skeletal muscle physiology, small vessel vasodilatory tone, and abnormal cellular biochemistry as correlates of diminished aerobic capacity in heart failure.

Aerobic capacity post transplantation

- Identified mechanisms that allow for restoration of nearly normal aerobic capacity in heart transplant recipients.

Steroid withdrawal in transplant recipients

- Described successful withdrawal of chronic steroid therapy in heart transplant recipients without untoward outcomes. A positive effect on aerobic capacity post heart transplantation was noted.

Description of aerobic capacity as a predictor of long-term outcome after heart transplantation.

Validation of non-invasive bioimpedance as a suitable methodology to determine cardiovascular hemodynamics.

Significant contribution to racial differences in the etiology, natural history, and response to medical therapy in heart failure.

Described novel immunosuppression regimen to preserve renal function in heart transplant recipients.

PUBLIC AWARENESS ADVOCACY AND ADVISORY HIGHLIGHTS

Established African American Task Force, Dallas Affiliate, American Heart Association.

Spearheaded efforts to create greater volunteer diversity, Texas Affiliate, American Heart Association.

Helped to create Texas Chapter, American College of Cardiology.

Co-Founder and first co-chair of the Texas Coalition to Reduce Heart Disease and Stroke.

- Major role in creating the first Cardiovascular Disease and Stroke Council of the Texas Department of Health as a legislatively mandated entity; House bill 2085, Article 25 passed May 1999 established the Council on Cardiovascular Disease and Stroke.

EDUCATION

- 1975 Southern University Laboratory High School, Baton Rouge, Louisiana
1977 Louisiana State University, (fall)
1978 Rutgers University, (summer)
1979 B.S. Southern University, Baton Rouge, Louisiana, Liberal Studies
1982 M.D. Tulane University School of Medicine, New Orleans, Louisiana

TRAINING

- 1982-85 Internship and Residency, Internal Medicine, Parkland Memorial Hospital, University of Texas Southwestern Medical Center, Dallas, Texas
1986-89 Fellowship, Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas

PROFESSIONAL EXPERIENCE

- 1976 Research Assistant, Biomedical Sciences Department, Southern University, Baton Rouge, Louisiana
1978 Research Chemist, Merck, Sharpe and Dohme Research Laboratories, Rahway, New Jersey
1979 Camp Counselor, American Diabetes Association
1985-86 Clinical Research Associate, Department of Cardiovascular Research, Tulane University School of Medicine, New Orleans, Louisiana
1985-86 Staff Physician, Departments of Internal Medicine and Ambulatory Care, New Orleans Veterans Administration Hospital, New Orleans, Louisiana
1987-89 Staff Physician, General Hospital of Lakewood, Dallas, Texas
1989- Attending Cardiologist, Coronary Care Unit, Parkland Memorial Hospital and Dallas Veterans Administration Hospital, Dallas, Texas
1989 Visiting Teaching Staff of the Department/Section of Medicine/Cardiology, St. Paul Medical Center, Dallas, Texas
1989- Clinical Cardiologist, Zale-Lipshy University Hospital, Dallas, Texas
1989-95 Assistant Professor of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas
1989 Attending Cardiologist, University of Texas Southwestern Medical Center/St. Paul Medical Center Cardiac Transplant Program, Dallas, Texas
1990-93 Advanced Cardiac Life Support Instructor
1990-93 Associate Director, Cardiac Rehabilitation Program, Parkland Memorial Hospital, Dallas, Texas
1990-96 **Director**, Cardiology Clinics, Parkland Memorial Hospital and University of Texas Southwestern Medical Center, Dallas, Texas
1990-92 Consulting Cardiologist, Renal Transplant Program, Parkland Memorial Hospital, Dallas, Texas
1991- **Director**, Congestive Heart Failure Program, University of Texas Southwestern

- Medical Center, Dallas, Texas
- 1992-93 **Acting Medical Director**, Coronary Care Unit, Parkland Memorial Hospital, Dallas, Texas
- 1993-94 **Acting Medical Director**, University of Texas Southwestern Medical Center, Cardiac Transplant Program, Dallas, Texas
- 1993- Associate Attending Staff, Department of Medicine, Division of Cardiology, St. Paul Medical Center, Dallas, Texas
- 1993-94 Medical Service, Research and Development Plan (MSRDP) Board of Directors Member-At-Large, University of Texas Southwestern Medical Center, Dallas, Texas
- 1994- **Medical Director**, Cardiac Transplant Program, University of Texas Southwestern Medical Center and St. Paul Medical Center, Dallas, Texas
- 1994-97 Pharmacy & Therapeutics Committee Member, Zale Lipshy University Hospital, Dallas, Texas
- 1995-97 Liaison Committee for Medical Education, University of Texas Southwestern Medical Center, Dallas, Texas
- 1995- **Associate Professor of Medicine**, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas
- 1996-2002 **Medical Director**, Baylor University Medical Center Cardiac Transplant Services/University of Texas Southwestern Medical Center, Dallas, Texas
- 1997- Finance & Audit Committee Member, St. Paul Medical Center, Dallas, Texas
- 1998- Transplant Review Committee Member, Baylor University Medical Center, Dallas, Texas
- 1998-2001 American Heart Association National Science Advisory and Coordinating Committee Member
- 2002-2004 American Heart Association National Science Advisory and Coordinating Committee Member
- 1998-2000 American Heart Association National Women & Minorities Leadership Committee Member
- 1998- Physician Peer Review and Assistance Committee, Parkland Memorial Hospital System
- 1999- Cardiac Transplant Research Database {CTRD} **Executive Committee**
- 1999-2001 American Society of Transplantation Patient Care and Education, Committee member
- 2001- Executive Committee, Ex-Oficio member, Heart Failure Society of America
- 2002- **Associate Dean of Clinical Affairs for St. Paul University Hospital; UT Southwestern Medical Center**
- 2002-2004 Editorial Board, *Journal of Cardiac Failure*
- 2002-2003 **Chairman**, Organ Transplantation Committee, Association of Black Cardiologists
- 2002- Editorial Board, *Progress in Transplantation*
- 2002-2003 Association of Black Cardiologists, Inc. Heart Failure Committee Member.
- 2002-2003 Association of Black Cardiologists, Inc. *Digest of Urban Cardiology* Committee Member.

MEMBERSHIPS AND PROFESSIONAL ORGANIZATIONS

American Diabetes Association - "Minority Initiative Committee"; **Board of Directors**, 1990-92

American College of Cardiology

Elected to Fellowship (F.A.C.C.) 2/3/92

American College of Cardiology, Secretary-Treasurer, Texas Chapter, 1993-95

American College of Physicians

American Heart Association

American Heart Association, Speakers Bureau

American Heart Association, Board of Directors, Dallas Division

American Heart Association, Board of Directors, Texas Affiliate

American Heart Association, Strategic Planning Committee, Texas Affiliate

American Heart Association, Council on Clinical Cardiology

American Heart Association, Chairman, Hypertension Task Force, Dallas Division

American Heart Association, First Vice-President, Dallas Division 93-94

American Heart Association, President Elect, Dallas Division 94-95

American Heart Association, President, Dallas Division 95-96

American Heart Association, First Vice-President, Texas Affiliate 96-97

American Heart Association, President Elect, Texas Affiliate 97-98

American Heart Association, President, Texas Affiliate 98-99

American Heart Association, Women and Minorities Leadership Committee, National Center 98-

2001

American Heart Association, Science Advisory and Coordinating Committee, National Center 98-2001

American Heart Association, Co-Chair, Nominating Committee, Texas Affiliate 2001

American Heart Association, Board of Directors, Texas Affiliate 2001-2002

American Heart Association: Communications Committee, Nominating Committee, Personnel Committee, Public Affairs Committee, Texas Affiliate 1999-2001

American Heart Association, Co-Chairperson of the Acute Event Strategic Group, National Center 2000-01

American Heart Association, National Board of Directors 2000-2002

American Heart Association, Honorary Board, Dallas Division 2001

American Heart Association, Long Range Planning/Budget Committee of the Council on Clinical Cardiology, July 1, 2001-June 30, 2003

American Heart Association, Communications & Customer Relations Coordinating Committee, National Center July 1, 2001-June 30, 2002

American Heart Association, National Council on Clinical Cardiology 1999-2001

American Heart Association, National Heart Failure and Transplant Committee Member; Co-Chair in 2000-2002, 1999-2001

American Heart Association, Committee on Clinical Science 2001-2002

American Heart Association, Council on Clinical Cardiology's Heart Failure and Transplantation

Committee, Chair, July 2001-June 2003

American Heart Association, Science Advisory and Coordinating Committee, July 2002-2003

American Heart Association, Strategic Assessment Group, Chair, 2002-

Dallas County Medical Society

Texas Medical Association

International Society for Heart and Lung Transplantation

American Society of Transplantation
 American Society of Transplantation, Patient Care & Education Committee 2001-2002
 Heart Failure Society of America, **Chair**, Membership Committee 2001
 Advisory Council to Improve Outcomes Nationwide in Heart Failure (ACTION HF)
 The Dallas Fresh Air Coalition, American Heart Association
Texas Coalition on Cardiovascular Disease and Stroke Coalition, Chair 2000-2002
 American Society of Transplantation -Patient Care & Education Committee 1999-2002
 Association of Black Cardiologists, Inc., **Chair**, Organ Transplantation Committee 2000-2002
 International Society on Hypertension in Blacks 1999-
 Texas Transplantation Society, Inc. 2001-
 Blue Cross Blue Shield of Texas, Cardiology Specialty Panel

INDUSTRY SPONSORED PROFESSIONAL AFFILIATIONS

Merck & Co. Speakers Bureau
 Cardiovascular Initiative Speakers Bureau
 GlaxoSmithKline Speakers Bureau
 Biosite Speakers Bureau
 National Visiting Professors Program, Monarch Pharmaceuticals
 US Heart Failure Advisory Council, Sponsored by SmithKline Beecham 1996-2000
 AstraZeneca, Toprol-XL[®] Heart Failure US Advisory Board 1999-2002
 Visiting Professor Program, GlaxoSmithKline, 2001-
 CardioDynamics, Medical Advisory Board 2000-2002
 SCIOS, Heart Failure Advisory Board 2000-2002
 Novartis Pharmaceuticals Speakers Bureau 2002
 Committee on Education and Intervention in Decompensated Heart Failure [Sponsored by Sanofi-Synthelabo] 2002

HONORS, AWARDS, AND SOCIETY MEMBERSHIPS

Eagle Scout, 1974
 High School Valedictorian, 1975
 National Achievement Scholar, 1975
 Honors Graduate (4.0), Southern University, 1979
 Alpha Kappa Mu Scholastic Society, 1979
 Alpha Chi Scholastic Society, 1979
 American Hospital Corporation Award for Scholarship, Leadership, and Character, Tulane University School of Medicine, 1982
Alpha Omega Alpha Honor Medical Society, Tulane University School of Medicine, 1982
 Outstanding Young Men of America, 1982
Internal Medicine House Staff Outstanding Teaching Award, 1991-'92
 "Top Doctors"; *D Magazine*, vol. 19, no. 7, July, 1992
 Canterbury Episcopal School, Board of Directors, member, 1993-
 Canterbury Episcopal School, **President-Elect**, 1998-'99
 ABC, Inc. Editorial Board, *Urban Cardiology*, 1993; 1994
 "Working Group on LV Dysfunction", 1993-'94; 1994-'95; 1995-'96

Congestive Heart Failure, **Associate Editor**, 1994-

Douglas Perry Volunteer of the Year Award, Dallas Division, American Heart Association, 1996

Nominee, JC Penney Golden Rule Award, 1996

International Society of Hypertension in Blacks (ISHIB) Fellow, 1996

Walter M. Kirkendall, M.D. Award for Outstanding Scientist/Educator Volunteer, American Heart Association, Texas Affiliate, 1996

Recipient of the Carl H. Westcott Distinguished Chair in Medical Research, October 1996

Recipient of the Dallas Heart Ball Chair in Cardiac Research, October 1996

Honorary Membership, Texas Academy of Physician Assistants, April 1997

“The Best Doctors in America”, 1998 and 2000

Outstanding Teacher, UT Southwestern Medical Center, Class of 2001, 1998-99

Stratmore’s Who’s Who, 2001-2002

Administrative Cabinet, First United Methodist Church, Duncanville, TX, 2001-

2001 Outstanding Research Award, International Society of Hypertension in Blacks

One of “America’s Leading Physicians,” *Black Enterprise* magazine, August 2001

Physician Volunteer of the Year Award, American Heart Association, Texas Affiliate, 2001

One of the “Top 330 Doctors of 2001,” *D Magazine*, October 2001

Daniel Savage Award Winner 2002 for Scientific Merit, Association of Black Cardiologists

National Register’s Who’s Who in Executives and Professionals, 2002-2003

The Dallas Assembly, 2002 [civic organization composed of leaders in business, law, commerce, government and medicine within the Dallas area]

Board of Directors, Family Place [shelter for battered women and their children]

The Frank P. Incaprerla, MD Award, Featured Speaker at the 26th Annual Lectureship, IMG Healthcare, LLC, April 18, 2002, Ritz Carlton Hotel, New Orleans, LA

Marquis Who’s Who in Medicine and Healthcare, 4th edition, September 2002

One of the “Top 381 Doctors of 2002,” Featured “Top Doctor” *D Magazine*, October 2002

ACADEMIC AND PROFESSIONAL INTERESTS

Congestive Heart Failure

Transplant Cardiology

Critical Care Cardiology

Exercise Physiology

Ethnic differences in cardiovascular disease

Hypertension

Pulmonary hypertension

Cardiac Catheterization (Hemodynamics)

Heart Failure in Special Populations

INVITED LECTURES [truncated #228 lectures 6/19/1990 – 12/21/1999]

02/15/00 – “Cardioprotection Benefits of Ace-Inhibitors”; DVDNVP Program, Tampa, FL.

03/10/00 – “Use of Carvedilol in African Americans with Heart Failure”; SmithKline Beecham, Laguna Beach, CA.

03/14/00 – “Diastolic Heart Failure”; **Chair**, American College of Cardiology session, Anaheim,

- CA.
- 04/13/00 – “Use of Beta Blockers in Heart Failure”; American College of Physicians, Philadelphia, PA.
- 04/29/00 – “Heart Transplantation for the Practicing Cardiologist”; American College of Cardiology, San Antonio, TX.
- 04/29/00 – “Primary and Secondary Prevention of Cardiovascular Disease”; American Heart Association, Corpus Christie, TX.
- 05/23/00 – “Heart Failure in African Americans”; Grand Rounds, Harlem Hospital, New York, NY.**
- 05/24/00 – “Heart Failure in African Americans”; Grand Rounds, St. Luke’s Hospital, New York, NY.**
- 05/28/00 – “Use of Beta Blockers in Heart Failure: Cellular and Metabolic Effects”; American Academy of Physicians Assistants, Chicago, IL.
- 06/03/00 – “Great Heart Failure Debates”; Accel Healthcare Communications, Marriott Hotel, Cincinnati, OH.
- “Is Right Heart Catheterization of Benefit in Heart Failure Management? – Con”;
“Do African Americans Respond Similarly to Medical Therapy for Heart Failure? – Pro”
- 07/15/00 – “Beta Blockers in Heart Failure”; **Chair**; Heart Failure Update; International Society of Hypertension in Black, Las Croabas, Puerto Rico. **Featured Lecture, Cardioprotective Effects of ACE-Inhibitors, the HOPE Trial**.”
- 07/22/00 – “Heart Failure in African Americans”; University of North Carolina Heart Failure Symposia, Amelia Island, FL.
- 08/20/00 – “Heart Failure Update: The Role of Beta Blockers”; International Society on Hypertension, Chicago, IL.
- 09/10/00 – “A Rationale for the Use of Beta Blockers in Heart Failure”; Heart Failure Society of America, Roche Pharmaceuticals, Boca Raton, FL.**
- 09/11/00 – “Acute Congestive Heart Failure-Case Management”; Heart Failure Society of America, Wyeth-Ayerst and Sanofi Pharmaceuticals CD Rom Series, Renaissance Hotel, Boca Raton, FL.**
- 09/12/00 – “Heart Failure in African Americans: Etiological Differences”; Opening Session, Lead Lecturer; Heart Failure Society of America, Boca Raton, FL.**
- 09/13/00 – “Treatment of Heart Failure in African Americans”; SmithKline Beecham, Heart Failure Society of America, Sunrise Series, Boca Raton, FL.
- 10/13/00 – “Use of Bio-Impedance to Determine Cardiovascular Hemodynamics: Results of a Validation Study”; CardioDynamics, San Diego, CA.
- 10/27/00 – “Hypertensive Heart Disease”; Internal Medicine Grand Rounds, University of Texas Southwestern Medical Center, Dallas, TX.**
- 11/10/00 – “Heart Failure in Special Populations”; SmithKline Beecham, Coreg Satellite Symposium, American Heart Association, New Orleans, LA.
- 11/10/00 – “Management of Heart Failure: Case Presentation”; Satellite Symposium, American Heart Association, New Orleans, LA.
- 11/29/00 – “Treating Heart Failure: How Do We Decide Which Therapy is Best?”; St. Mary’s Hospital, Current Health Focus Lecture Program, Evansville, IN.
- 12/13/00 – “New Advances in the Treatment of Congestive Heart Failure”, Wichita Falls, TX.
- 01/08/01 – “Heart Failure in African Americans”; Special Lecture, Wayne State**

University; Detroit, MI.

- 01/20/01 – **“Congestive Heart Failure in African Americans: Role of Blocking the RAS by Single Agents and Combinations”**; Association of Black Cardiologists, Sixth Annual Cardiovascular Summit, Caribe Royale Resort, Lake Buena Vista, FL.
- 01/20/01 – “Management of Acute Decompensated Heart Failure: A Physicians Perspective”; SCIOS, Critical Care Nurses Advisory Board, Lake Buena Vista, FL.
- 02/03/01 – “Congestive Heart Failure”; Current Trends 2001: Family Practice Update; The University of Texas Health Center at Tyler, Tyler, TX.
- 02/09/01 – **“Change in the Natural History of CAD- ‘We Now Have HOPE’”**; Cardiology Grand Rounds, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
- 2/10/01 – “Cardiovascular Risk Factors in the African American Population”; Preventive Cardiology Forum XI: Preventive Cardiovascular Disease in Diverse Populations; American Heart Association, Houston Division, Houston, TX.
- 02/17/01 – **“Treatment Strategies: Focus on Special Populations”**; Pri-Med West 2001, Vascular Protection: Managing the Renin-Angiotensin System, CME Breakfast Symposium, Long Beach, CA.
- 02/27/01 – “Management of Hypertension”; Southwest Regional Cardiovascular Update 2001; American Heart Association Cardiovascular Nurses Committee and Physician’s Committee, Fort Worth, TX.
- 03/06/01 – “Congestive Heart Failure in Special Populations”; Winters Center Conference, Houston, TX.
- 03/17/01 – “Heart Failure in the African American Population – Impact on Current Treatment Recommendations”; American College of Cardiology Annual Meeting; LSU Health Sciences Center; The Peabody Hotel, Orlando, FL.
- 03/17/01 – “Session V: Heart Failure”; **Co-moderator**, American College of Cardiology Annual Meeting; Association of Black Cardiologists, Sheraton World Resort, Orlando, FL.
- 03/17/01 – **Chair**, Sanofi & Michigan Medical School Primacor Management Team; American College of Cardiology, Wyndham Hotel, Orlando, FL.
- 03/23/01 – “Evaluation of Heart Failure Clinical Trials with Reference to Gender and Ethnicity”; 6th Annual Cardiovascular Management for Clinicians; Radisson Resort & Spa, Scottsdale, AZ.
- 04/11/01 – “Beta-Blockade in Heart Failure Management”; Carvedilol 2001 Visiting Faculty Program, St. Louis, MO.
- 04/20/01 – **“Heart Failure Demographics”**; Sanofi-Synthelabo, Inc. Advisory Board Meeting **“Building Value in Heart Failure Management,”**, Paris, France.
- 05/16/01 – “Hypertension and Left Ventricular Function: Case Studies”; 16th Annual Scientific Meeting American Society of Hypertension, “From Hypertension to Heart Failure-Vasculature and Myocardial Mechanisms: The Impact on Clinical Practice,” San Francisco Hyatt Regency Embarcadero, San Francisco, CA.
- 05/24/01 – **“Racial Differences in the Response to Neurohormonal Blockers in Heart Failure”**; Grand Rounds, University of California at San Diego, Division of Cardiology, San Diego, CA.
- 05/26/01 – **“Are There Racial Differences in the Pathophysiology and Response to Therapy of Heart Failure”**; 7th Annual UCSD Heart Failure Symposium, University of California at San Diego, Division of Cardiovascular Medicine, San Diego, CA.

- 06/19/01 – “Beta-blockade in Heart Failure Management”; Carvedilol 2001 Visiting Faculty Program, The Woodlands Resort & Conference Center, The Woodlands, TX.
- 06/23/01 – “African American Response to Heart Failure Treatment: Old Questions, New Analyses, Promising Management”; Carvedilol Consultants’ Educational Update Forum Central, Palmer House Hilton, Chicago, IL.
- 07/07/01 – “Treatment of Heart Failure in African Americans: Clinical Update”; **Chair & Speaker**, International Society of Hypertension in Blacks 16th Annual International Interdisciplinary Conference, “Heart Failure in Special Populations: Featuring Just Released Data on Treating African Americans with Heart Failure”; Mandalay Bay Resort & Casino, Las Vegas, NV.
- 07/08/01 – “Congestive Heart Failure Management in African Americans: Role of Blocking the RAS by Single Agents & Combinations”; International Society of Hypertension in Blacks 16th Annual International Interdisciplinary Conference, Novartis Pharmaceuticals Special Dinner Symposium “Cardiovascular Risk Management for African Americans in the 21st Century: Focus on Blocking the RAS”; Mandalay Bay Resort & Casino, Las Vegas, NV.
- 07/09/01 – “Recent Beta Blocker Evidence: A Clinical Update”; **Co-chair & Speaker**, International Society of Hypertension in Blacks 16th Annual International Interdisciplinary Conference, Morehouse School of Medicine & the International Society of Hypertension in Blacks, “Transitioning Beta Blockers From Clinical Guidelines to Everyday Practice: An Interactive Case-Study Approach”; Mandalay Bay Resort & Casino, Las Vegas, NV.
- 07/11/01 – “Beta-Blockade in Heart Failure Management”; 2001 Carvedilol Visiting Faculty Program, Burton & Doyle, New York, NY.
- 07/21/01 – “Heart Failure Management in African Americans—Same or Different Approaches Needed?”; Heart Failure Management 2001: Established Therapy and New Frontiers; UNC School of Medicine, Amelia Island, FL.
- 07/24/01 – “Beta-Blockade in Heart Failure Management”; Carvedilol 2001 Visiting Faculty Program, 82 Queen Street Restaurant, Charleston, SC.
- 09/07/01 – “Minorities in Academic Medicine”; How to Become a Cardiovascular Investigator, American College of Cardiology & American Heart Association, The Heart House, Bethesda, MD.
- 09/08/01 – “Failure in Patients with Diabetes”; Carvedilol Advisory Panel Meeting, Sessions I, II, III; Workshop III; Heart Failure Society of America 5th Annual Scientific Meeting, GlaxoSmithKline, Willard Inter-Continental Hotel, Washington, DC.**
- 09/11/01 – “Race”; Sunrise Series: “Extending the Benefits of Beta-Blockade to Patients Across the Heart Failure Spectrum, Part II: Important Subgroups: Old Questions, New Analyses”; Heart Failure Society of America 5th Annual Scientific Meeting, GlaxoSmithKline, Marriott Wardman Park Hotel, Washington, DC.**
- 09/12/01 – “Non-invasive Hemodynamic Monitoring: Impedance Cardiography (ICG): Technology Overview, Validity and Current Clinical Studies”; Special Symposium: “Noninvasive Hemodynamic Monitoring in Heart Failure: Utilization of Impedance Cardiography (ICG)”; Heart Failure Society of America 5th Annual Scientific Meeting, Cardiodynamics International Corporation & GE**

**Medical Systems Information Technologies, Marriott Wardman Park Hotel,
Washington, DC.**

- 10/03/01 – “Heart Failure in African Americans: Is Hypertension the Culprit?”;
Hypertension Grand Rounds, Case Western Reserve University, Cleveland, OH.**
- 10/06/01 – “Heart Failure in African Americans: Same or Different Approach?”; Heart Failure Symposium 2001; WakeMED & UNC Area Health Education Centers Programs (AHEC), Raleigh, NC.
- 10/06/01 – “The Physiologic & Diagnostic Role of BNP in Heart Failure”; Heart Failure Symposium 2001; WakeMED & UNC Area Health Education Centers Programs (AHEC), Raleigh, NC.
- 10/10/01 – “Race and the Response to Therapy for Heart Failure”; Carvedilol 2001 Visiting Faculty Program, Chateau Briand, New Orleans, LA.
- 10/11/01 – “Treatment of Advanced Heart Failure: Is there a Role for Beta-Blockade?”;
Cardiology Grand Rounds, Tulane University, New Orleans, LA.**
- 11/01/01 – “Advances in the Therapy of Congestive Heart Failure: The Role of Beta-Blockade”; Kansas City Southwest Clinical Society; 2001 Fall Clinical Conference, Overland Park Marriott Hotel, Overland Park, KS.
- 11/01/01 – “”; Carvedilol 2001 Visiting Faculty Program, Capital Grille; Kansas City, KS.
- 11/03/01 – “New Directions in Cardiac Protection: A Case-Based Approach”; AstraZeneca & Centric Medical Communications, Inc., Aldredge House, Dallas, TX.
- 11/05/01 – “New Concepts in the Management of Heart Failure: An Interactive Case Study Review”; Novartis Pharmaceuticals; CME program, Four Seasons Spa & Resort, Las Calinas, TX.
- 11/08/01 – “The Cardiovascular Continuum”; Novartis Pharmaceuticals, Nick & Sam’s, Dallas, TX.
- 11/09/01 – “Congestive Heart Failure”; Texas Academy of Internal Medicine & Texas Chapter of the ACP-ASIM Annual Meeting, Marriott at the Capitol Hotel, Austin, TX.
- 11/12/01 – “Progress in Understanding Racial Differences in Outcomes and Management of Heart Failure”; American Heart Association Scientific Session, Orange County Convention Center, Anaheim, CA.
- 11/13/01 – “Back to Beta-Blockers: An Evidence Approach to Treating Hypertension, CAD and CHF”, George Washington University, Webcast, AstraZeneca & Centric Medical Communications, Inc., Coast Media Technologies, Irvine, CA.
- 11/17/01 – “Consideration of Race in Clinical Trials”; Race and Medicine Consultant’s Conference; Association of Black Cardiologists Executive Board Meeting, Copperwynd Resort, Phoenix, AZ.
- 11/17/01 – “The Impacts of Racism on Health”; Race and Medicine Consultant’s Conference, Association of Black Cardiologists Executive Board Meeting, Copperwynd Resort, Phoenix, AZ.
- 11/29/01 – “A Novel Paradigm in the Management of Heart Failure: BNP It’s Role as a Diagnostic and Therapeutic Tool”; SCIOS, Bistro Louise, Ft. Worth, TX.
- 12/08/01 – “The Hypertension Timeline: 5-10 Years Predicting the Future Antihypertensive Market”; GlaxoSmithKline Hypertension Advisory Board Meeting, The Mansion at Turtle Creek, Dallas, TX.
- 12/12/01 – “”; SCIOS, Austin, TX.
- 01/07/02 – “Heart Failure in African Americans”; Duke University Medical School,**

Cardiology Grand Rounds, Durham, NC.

- 01/08/02 – “Hypertensive Heart Disease-Mechanisms and Insight into Future Treatment Strategies”; DCRI Research Conference, Duke University Medical School, Durham, NC.
- 01/19/02 – “Neurohormonal Activation in HF: Lessons Learned from Val-HeFT”; 7th Annual Cardiovascular Summit: Reducing the CV Risk Burden: The Role of AII Blockade; Association of Black Cardiologists, Inc., Caribe Royale Resort, Lake Buena Vista, FL.
- 01/19/02 – “Hospitalization for CV Disease in African-Americans: Reducing the Burden”; 7th Annual Cardiovascular Summit: Reducing the CV Risk Burden: The Role of AII Blockade; Association of Black Cardiologist, Inc., Caribe Royale Resort, Lake Buena Vista, FL.
- 01/22/02 – “An Update on Advanced Heart Disease”; The President’s Research Council 2002: Supporting the Advancement of Medicine and Science, Simmons and Hamon Biomedical Research Buildings, Dallas, TX.
- 01/26/02 – “Success with Heart Failure: New Strategies to Reverse Acute Decompensation”; SCIOS, Inc. Speaker Training, Omni Mandalay Hotel, Las Calinas, TX.
- 02/02/02 – **Heart Failure 2002; The Cutting Edge. Program Chair, UT Southwestern and St. Paul University Hospital, Dallas TX. “Heart Failure 2002; Managing the Polypharmacy”**
- 02/04/02 – “An Update on Heart Failure: New Perspectives on Neurohormonal Antagonism”; Carvedilol 2002 Visiting Faculty Program, Ritz-Carlton, St. Louis, MO.
- 02/12/02 – “Hypertension to Heart Failure: The Cardiovascular Continuum”; **Grand Rounds & Visiting Professor**, Howard University Medical Center, Washington, DC.
- 02/12/02 – “An Update on Heart Failure”; Carvedilol 2002 Visiting Faculty Program, Charllestons Restaurant, Washington, DC.
- 02/13/02 – “An Update on Heart Failure: Improved Treatment Strategies”; **Internal Medicine Grand Rounds**, Carvedilol 2002 Visiting Faculty Program, Potomac Hospital, Woodbridge, VA.
- 02/13/02 – “An Update on Heart Failure: Addressing Early Stage Disease”; 2002 Carvedilol Visiting Faculty Program, Smith & Wolensky’s, Washington, DC.
- 03/02/02 – “New Analyses: COPERNICUS and CAPRICORN”; Carvedilol Speaker Update Meeting, Omni Mandalay, Irving, TX.
- 03/02/02 – “2001 ACC/AHA Guidelines for the Management of Chronic Heart Failure: From Hypertension to Heart Failure”; Carvedilol Speaker Update Meeting, Omni Mandalay, Irving, TX.
- 03/16/02 – “Pro Position--ACE Inhibitors are an Effective Treatment in African-Americans”; American College of Cardiology 51st Annual Scientific Session, Association of Black Cardiologists, Inc., Sheraton Atlanta Hotel, Atlanta, GA.
- 03/16/02 – “Noninvasive Hemodynamic Monitoring in Heart Failure: Utilization of Impedance Cardiography (ICG)”; American College of Cardiology 51st Annual Scientific Session, University of Minnesota, Office of Continuing Education, Medical School and CardioDynamics, Inc., The Omni at CNN, Atlanta, GA.
- 03/17/02 – “Acute Decompensated Congestive Heart Failure in African-American and Their Response to Treatment with Nesiritide”; American College of Cardiology 51st Annual

- Scientific Session, Atlanta, GA.
- 03/17/02 – “Hypertension: The Use of ARB’s”; Wine Tasting Event; American College of Cardiology 51st Annual Scientific Session, Sanofi-Synthelabo, Inc. and Bristol-Myers-Squibb, Ritz Carlton-Buckhead, Atlanta, GA.
- 03/19/02 – “ACC Session: Heart Failure Prognostic Factors/Outcomes II”; **Co-chair**, American College of Cardiology 51st Annual Scientific Session, Georgia World Congress Center, Atlanta, GA.
- 03/19/02 – “Treatment in End-Stage Heart Failure: Which and When?”; Joint Symposium: Association of Black Cardiologists and the American College of Cardiology—Advanced Heart Failure: Optimal Selection of Therapeutic Options. American College of Cardiology 51st Annual Scientific Session, Georgia World Congress Center, Atlanta, GA.
- 03/20/02 – “Racial Differences in Response to Heart Failure Therapy”; **Lunchtime Panel Chair**, American College of Cardiology 51st Annual Scientific Session, Georgia World Congress Center, Atlanta, GA.
- 04/18/02 – “**Management of Acute Decompensated Heart Failure**”; **Grand Rounds**, **Pendleton Methodist Hospital, New Orleans, LA.**
- 04/18/02 – “An Update on Heart Failure”; **26th Annual IMG Lectureship**, Ritz Carlton Hotel, New Orleans, LA.
- 04/24/02 – “Contemporary Management of Heart Failure – An Approach Based on Neurohormonal Mechanisms”; Internal Medicine Section Conference, Methodist University Hospital, Memphis, TN.
- 04/27/02 – “Review of Optimal Medical Therapy for Congestive Heart Failure: What Have We Learned?”; American College of Cardiology Extramural Program, Cardiology Fiesta in San Antonio: Update on Cardiac Diagnostic and Therapeutic Techniques: Focus on Congestive Heart Failure, 10th Anniversary, San Antonio, TX.
- 05/15/02 – “ β -Blockade in Left Ventricular Dysfunction – The Heart Failure Experience”; Carvedilol Hypertension Advisory Panel: Carvedilol Application Across the Metabolic-Cardiovascular Spectrum, Millennium Broadway, New York, NY.
- 05/16/02 – “**Reducing Cardiovascular Risk in Patients with Diabetes**”; **17th Annual Scientific Meeting & Exposition of the American Society of Hypertension, Special Symposium: Rationale Behind the Use of Cardioprotective Pharmacotherapy in the Metabolic Syndrome: A Case Based Approach**, New York Marriott Marquis, New York, NY.
- 05/16/02 – “**Current Approaches and Controversies in Heart Failure Management**”; **4th Annual Cardiology Symposium and Department of Medicine Grand Rounds: Current & Emerging Trends in the Management of Heart Failure**, SUNY Downstate Medical Center, Brooklyn, NY.
- 05/17/02 – “**Hypertension and CHF**”; **17th Annual Scientific Meeting & Exposition of the American Society of Hypertension, Special Symposium: Hypertension and the Heart: How to Prevent and Treat LVH, CAD, and CHF**, New York Marriott Marquis, New York, NY.
- 06/10/02 – “**Optimizing Beta-Blocker Therapy in Heart Failure and the Prevention of Sudden Cardiac Death**”; **ISHIB 2002: 17th Annual International Interdisciplinary Conference on Hypertension and Related Risk Factors in Ethnic Populations**,

Chair and Speaker, Lunch Symposium: Managing CVD in a Complicated Patient Population: Emerging Treatments for Minimizing the Burden of Comorbidity, Loews Miami Beach Hotel, Miami, FL.

- 06/11/02** – “**Cardiovascular Risk Modifications in African-Americans: Focus on Congestive Heart Failure**”; ISHIB 2002: 17th Annual International Interdisciplinary Conference on Hypertension and Related Risk Factors in Ethnic Populations, **Co-chair and Speaker, Special Dinner Symposium: The Role of A II Blockade in Cardioresenal Risk Reduction in Blacks, Loews Miami Beach Hotel, Miami, FL.**
- 06/14/02 – “Congestive Heart Failure Management: Should African Americans be Treated Differently”; Georgia State Medical Association’s 109th Annual Convention, Crowne Plaza Resort, Hilton Head Island, SC.
- 06/19/02 – “Contemporary Management of Hypertension-A Focus on ARBs”; Sanofi-Synthelabo, Inc., Med Providers Clinic, Dallas, TX.
- 06/19/02 – “CVD and Stroke in Texas-A chronicle of the Texas Coalition to Reduce Heart Disease and Stroke”; 2002 Cardiovascular Disease & Stroke Summit, Four Points Riverwalk Sheraton, San Antonio, TX.
- 06/20/02 – “Pharmacology and Other Interventions”; Session II: Racial & Gender Differences, Health Issues and Concerns of Women of Color: A Call to Action III--A Focus on Cardiovascular Disease: Centering Mind & Body through Prevention and Intervention, Howard University Women’s Health Institute, Howard University Hospital, Washington, DC.
- 06/27/02 – “How to Set Up a Heart Failure Clinic”; Scios, Inc., Royal Palms Hotel & Casitas, Phoenix, AZ.
- 06/28/02** – “**Neurohormonal Modulation in Heart Failure-An Evolving Concept**”; **Grand Rounds, The University Medical Center, Arizona Heart Institute, Tucson, AZ.**
- 07/20/02 – “Heart Failure Management in African Americans: Same or Different Approaches Needed?”; Session III: Future Directions in the Management of Heart Failure-Heart Failure Management 2002: Established Therapy and New Frontiers, UNC School of Medicine, Amelia Island Plantation, Amelia Island, FL.
- 07/23/02 – “Contemporary Strategies for Achieving Blood Pressure”; Diovan Advisory Board Meeting, Novartis Pharmaceuticals Corporation, The Mansion on Turtle Creek, Dallas, TX.
- 07/25/02 – “Nesiritide: Is There a Role for Outpatient Therapy?”; SCIOS, Inc. Investigator’s Day, The New York Palace Hotel, New York, NY.
- 07/29/02 – “The Cardiovascular Continuum”; Diovan Advisory Board Meeting, Novartis Pharmaceuticals Corporation, Morton’s of Chicago, Washington, DC.
- 07/30/02** – “**Hypertension to Heart Failure: Disease Management Across the Cardiovascular Continuum**”; **Medicine Grand Rounds, Inova Fairfax Hospital, Falls Church, VA.**
- 08/02/02 – “Impact of Beta-Blockade Therapy Across the Cardiovascular Continuum”; 2002 Carvedilol Visiting Faculty Program, Roy’s Restaurant, Tampa, FL.
- 08/16/02 – Breakout Group 5: Definition and Use of Surrogate Endpoints for Clinical Trials; Heart Failure Mountaintop Retreat 2002, Keystone Resort, CO.
- 08/21/02** – “**Heart Failure: Review of New Practice Guidelines and Benefits of Beta-Blockade**”; **Grand Rounds, Montgomery Cardiovascular Associates, Montgomery,**

AL.

- 08/24/02 – “Nesiritide—Does It Have a Role as Intermittent Outpatient Therapy in Heart Failure”; 2002 Summer ADHERE Registry Meeting, Four Seasons Hotel, Boston, MA.
- 09/21/02 – “Cardioprotective Evidence for the Role of Beta-Blockade in African Americans”; Heart Failure Society of America 6th Annual Scientific Meeting, Vascular Biology Working Group Meeting, Boca Raton Resort & Club, Boca Raton, FL.**
- 09/24/02 – Heart Failure Society of America Membership Committee Meeting; Chair**
- 09/24/02 – “Nitric Oxide Role in Heart Failure: Pathophysiology and Treatment”; Heart Failure Society of America 6th Annual Scientific Meeting, Nitromed, Inc. & the University of Minnesota, Boca Raton Club & Resort, Boca Raton, FL.**
- 10/07/02 – “Heart Failure in African Americans—Emerging Data and Persistent Questions”; Cardiovascular Research Conference, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN.
- 10/30/02 – “Heart Failure in African Americans”; Cardiology Grand Rounds, Boston University, Boston, MA.**
- 11/08/02 – “Newest Paradigm in Heart Failure: A Review of Natriuretic Peptides”; Cardiology Grand Rounds, University of Colorado, Denver, CO.**
- 11/08/02 – “Beta-Blockade: Preventing End Organ Damage”; Pri-Med Regional Medical Conference, Denver, CO.
- 11/19/02 – “Heart Failure: Cytokines, Autoantibodies, and Circulating Neurohormonal Factors”; **Chair**, American Heart Association 75th Annual Scientific Sessions, Chicago, IL.
- 11/20/02 – “How to Manage Patients with Acute Heart Failure Decompensation”; How to Noon Conference Lecture Series, American Heart Association 75th Annual Scientific Sessions, Chicago, IL.
- 11/20/02 – “Plenary Session XIII: Heart Failure 1995-2005”; **Chair**, American Heart Association 75th Annual Scientific Sessions, Chicago, IL.
- 12/07/02 – “Congestive Heart Failure: 2003 Preview”; Louisiana Chapter of the American College of Cardiology 2002 Annual Meeting Scientific Session, New Orleans, LA.
- 01/07/03 – “New Therapies in the Treatment of Congestive Heart Failure”; Texas Academy of Family Physicians, The Old Warsaw, Dallas, TX.
- 01/22/03 – “Treatment of Congestive Heart Failure in African American Patients”; Cardiology Grand Rounds, Sinai Samaritan Hospital, Milwaukee, WI.**
- 01/22/03 – “Treatment of Congestive Heart Failure in African American Patients”; 2003 Visiting Faculty Program, GlaxosmithKline, Boulevard Inn, Cudahy Tower, Milwaukee, WI.
- 01/28/03 – “New Therapies in the Treatment of Congestive Heart Failure”; Texas Academy of Physicians, Prime CME Lecture and Dinner, Brennan’s, Houston, TX.

02/07/03 –“Preventing Heart Failure Through the Use of Beta Blockers”; Congestive Heart Failure Symposium, Texas Transplant Institute, Pedrotti’s North Wind Ranch, San Antonio, TX.

03/06/03 – “Heart Failure Update 2003”; **Medicine Grand Rounds**, Pennington Medical Research Center, Baton Rouge, LA.

03/14/03 –“Heart Failure—Improving Outcomes in Contemporary Practice”; **Medical Grand Rounds**, Lenox Hill Hospital, New York, NY.

REVIEWER

Journal of the American College of Cardiology

Circulation

American Journal of Cardiology

American Heart Journal

Clinical Cardiology

EDITORIAL BOARD

Journal of Cardiac Failure

Congestive Heart Failure

GRANT SUPPORT

"Reversible Skeletal Muscle Energetics after Cardiac Transplantation"; American Heart Association, Texas Affiliate, 1990-92

MULTICENTER STUDY PARTICIPATION

A Phase III Multi-Center Study of the Comparative Efficacy and Safety of Intravenous Milrinone and Dobutamine on Left Ventricular Dysfunction in Congestive Heart Failure Following Myocardial Infarction

Evaluation of the Safety and Efficacy of Zofenopril Calcium Administered BID to Patients with Chronic Heart Failure

Efficacy of Fosinopril Sodium in Patients with Chronic Heart Failure not Receiving Digoxin Therapy

A Phase III, Multicenter, Open Label Study to Evaluate the Efficacy and Safety of Intravenous Milrinone on Left Ventricular Dysfunction in Patients with Congestive Heart Failure Acute Myocardial Infarction

A Randomized, Phase III, Placebo Controlled Survival Study of Oral Milrinone in Patients with Severe Heart Failure (PROMISE)

A Double-Blind, Randomized, Placebo-Controlled Study of the Effect of Flosequinan on the Survival of Patients with Chronic Congestive Heart Failure (PROFILE)

A Six-Month, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Comparison of Oral Carvedilol b.i.d. in Patients with Congestive Heart Failure, NYHA Class II-IV (MOCHA)

A Randomized Multiple Dose Study of the Chronic Administration of Vesnarinone in Heart Failure

A Randomized, Double-Blind, Dose Response, Positive Control Comparative Evaluation of the Efficacy and Safety of OPC-18790 in the Treatment of Patients with Decompensated Heart Failure (RESPIT)

A Study of Oral Carvedilol in NYHA Class I-IV Congestive Heart Failure

A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study of the Chronic Administration of Vesnarinone in Heart Failure (VEST)

Beta-Blocker Evaluation of Survival Trial (BEST)

A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effects of Ro 47-0203 (Bosentan) on the Morbidity and Mortality of Patients with Moderate to Severe Chronic Heart Failure

Inhibition of MetalloProtease in a Randomized Exercise and Symptoms Study in Heart Failure (IMPRESS)

The Effect of Sustained-Release Moxonidine on Mortality and Morbidity in Patients with Congestive Heart Failure (MOXCON)

National Heart, Lung, and Blood Institute of the National Institutes of Health and Thermo Cardiosystems, Inc. Protocol: Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH)

Baylor Research Institute, A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination with CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation (ZENAPAX)

Immunex, Multicenter, Double-Blind, Randomized, Placebo Controlled, Phase II/III Study of Efficacy and Safety of Recombinant Human Tumor Necrosis Factor Receptor (P75) Fc Fusion Protein (TNFR:Fc) (Etanercept) in Patients with Chronic Heart Failure Class II-IV (RENAISSANCE)

Bristol-Myers-Squibb, Omapatrilat vs. Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)

CardioDynamics International Corporation, Prospective Evaluation and Identification of Decompensation by Impedance Cardiography Test (PREDICT)

National Heart, Lung, and Blood Institute of the National Institutes of Health, Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE)

Principal Investigator, BIG substudy, ESCAPE trial (Bioimpedance Cardiography Trial)

Nitromed. African-American Heart Failure Trial (A-HeFT)

Steering Committee Member

Duke Clinical Research Institute, Surgical Treatment for Ischemic Heart Failure Trial (STICH)

Executive Committee Member, Chair, Minority Subcommittee

Scios, Inc. Acute Decompensated Heart Failure Registry (ADHERE)

Steering Committee, ADHERE Longitudinal Module

Scios, Inc. Management of Patients with CHF After Hospitalization – Follow Up Serial Infusion of Natrecor® - FUSION 1, A Pilot Study (FUSION-1)

GlaxoSmithKline, Inc. Organized Program to Initiate Life-saving treatment In hospitalized patients with Heart Failure (OPTIMIZE-HF)

Steering Committee

PUBLICATIONS

I. ABSTRACTS

Levine BD, Buckey JC, Fritsch JM, **Yancy CW**, Watenpaugh DE, Eckberg DL, Blomqvist CG. Physical fitness and orthostatic tolerance: the role of the carotid baroreflex. *Clin Res* 1988;36(3):295A.

Yancy CW, Vissing S, Buckey JC, Bellomo JF, Firth BG, Blomqvist CG. Maximal conductance versus maximal oxygen uptake in patients with congestive heart failure. (Presented at the American College of Cardiology, 3/88). *JACC* 1988;11(2):73A.

Yancy CW, Vissing SF, Bertocci LA, Nunnally RL, Blomqvist CG. Metabolic correlates of peripheral blood flow in congestive heart failure. (Presented at the American Heart Association Annual Meeting, 11/88). *Circulation* 1988;78(4):496II.

Yancy CW, Parsons D, Lane L, Carry M, Firth BG, Blomqvist CG. Capillary density, fiber type and enzyme composition of skeletal muscle in congestive heart failure. (Presented to the American College of Cardiology Annual Meeting, 3/89). *JACC* 1989;13(3):38A.

Olivari MT, **Yancy CW**, Rosenblatt R, Ring WS. Use of gradual exercise protocol demonstrates improved exercise capacity after heart transplant. *JACC* 1993;21(2):189A.

Jost CMT, **Yancy CW**, Jessen ME, Baldwin BJ, Horn VPH, Ring WS, Olivari MT. Improved exercise tolerance after heart transplantation. *Chest* August 1993.

Escobar JM, Olivari MT, Baldwin BJ, Horn VPH, Ring WS, **Yancy CW**. One-year survival in patients determined to be too well for cardiac transplantation. *Circulation* 1994;90(4):I-152.

Escobar JM, Olivari MT, Solomon, MA, Ring, WS, **Yancy CW**. Factors influencing exercise capacity after orthotopic heart transplantation. *Circulation* 1994;90(4):I-420.

Olivari MT, **Yancy CW**, Ring WS, Baldwin BJ, Horn VP. Effect of steroid withdrawal on cardiac allograft function and exercise tolerance. *JACC* 1994.

Escobar JM, Solomon MA, Hawley-Debes C, Olivari MT, **Yancy CW**. Racial differences in a heart failure referral program. (Presented at the Association of Black Cardiologists national meeting 3/94).

Yancy C, Graczyk F, Escobar J, Solomon M, Ring, WS. Reduction of rejection when pravastatin is added to a rapid steroid taper protocol. *J Heart Lung Transplant*. 1996;15:S59. (Presented at the 16th Annual International Society on Heart and Lung Transplantation Meeting.)

Yancy CW, Escobar JM, Solomon MA, Meyer DM, Ring WS. Management of ischemic heart disease in patients referred for cardiac transplantation. *JACC* 1997;29(2):28A.

Yancy C, Fowler MB, Colucci WS, Gilbret EM, Lukas MA, Young ST, US Carvedilol Heart Failure Study Group. Response of black heart failure patients to Carvedilol. *JACC* 1997;29(2):284A.

Yancy CW, Graczyk F, Escobar JM, Solomon MA, Meyer DM, Ring WS. Factors which predict successful wean of steroid therapy after heart transplantation. (Accepted for ASTP '97 Scientific Session)

Ballantyne CM, Short BC, Bourge RC, Eisen HJ, Fishbein DP, Kubo SH, Lake KD, Badovancevic B, Taylor DO, Ventura HO, **Yancy CW**, Young JB. Lipid treatment and survival after heart transplantation. *JACC* 1998;31(2):157A.

DeSalvo TG, Naftel DC, Kasper EK, Rayburn BK, Leier CV, Massin EK, Cintron GB,

Yancy CW, Keck S, Aaronson K, Kirklin JK & the Cardiac Transplant Research Database. The differing hazard of lymphoma vs. other malignancies in the current era - a multiinstitutional study. *J Heart Lung Transplant*. 1998;17(1):108.

Franco F, Solomon MA., Fernandez E., **Yancy CW**, and Peshock RM. Effect of left ventricular filling pressure as measured by pulmonary capillary wedge pressure on right ventricular function in patients with congestive heart failure. *JACC* 1999;33:195A.

Franco F, Solomon MA, McColl R, **Yancy CW**, Peshock RM. Evidence of early reverse remodeling of the right ventricle in congestive heart failure after intensive medical therapy targeted to reduce afterload. *JACC* 1999;33:197A.

Yancy CW, Naftel DC, Foley BA, Kobashigawa JA, Pitts DE, Rodeheffer RJ, Renlund DG, Ewald G, Kaiser G, McGiffin DC for the Cardiac Transplant Research Database Group. Death after heart transplantation: a competing outcomes analysis. (Presented at The International Society for Heart and Lung Transplantation 20th Annual Meeting and Scientific Sessions, April 5-8, 2000 in Osaka, Japan).

Rosenberg PB, Kaiser PA, Baliga RR, Solomon MA, Drazner MH, Hynan LA, Ring WS, **Yancy CW**. Is aerobic capacity at one-year post-heart transplantation associated with long term survival? (Presented at The International Society for Heart and Lung Transplantation 20th Annual Meeting and Scientific Sessions, April 5-8, 2000 in Osaka, Japan).

Neily JB, Toto KH, Gardner EB, Rame JE, Rosenberg PB, **Yancy CW**, Sheffield MA, Drazner MH. Dietary sodium: what do heart failure patients know? *J Card Fail* 2000;6(3):77.

Drazner MH, Toto KH, Gardner EB, Rosenberg PB, Rame JE, **Yancy CW**, Sheffield MA. Beta-blocker administration to patients with chronic heart failure in an urban county hospital. *J Card Fail* 2000;6(3):79.

Rosenberg PB, Drazner MH, Dimaio JM, Kaiser P, Meyer DM, Ring WS, **Yancy CW**. Induction with basiliximab preserves renal function following cardiac transplantation. *Circulation*, 2000;102(18):738(suppl. II)

Drazner MH, Thompson BS, Rosenberg PB, Dries DL, **Yancy CW**. Does impedance cardiography accurately determine cardiac hemodynamics in patients with heart failure? *JACC* 2001;37(2):207A.

Rame JE, Sheffield MA, Dries DL, Gardner EB, Toto KH, **Yancy CW**, Drazner MH. Outcomes following discharge from an urban county hospital emergency room with a primary diagnosis of heart failure. *JACC* 2001;37(2):219A.

Costanzo MR, Eisen HJ, Brown RN, Mehra M, Benza R, Torre G, **Yancy CW**, Davis S, Mccloud M, Kirklin J, the Cardiac Transplant Research Database Group at University of Alabama, Birmingham. Are there specific risk factors for fatal allograft vasculopathy? an

analysis of over 7,000 cardiac transplant patients. *J Heart Lung Transplant*, 2001;20(2):152.

Vriesendorp E, Rosenberg PB, Drazner MH, Dries D, Kaiser PA, DeMaio JM, Meyer DL, Ring WS, **Yancy CW**. Induction with basiliximab preserves renal function following cardiac transplantation. *Am J Transplant* 2001;1:432(suppl. I).

Yancy CW, Naftel DC, Renlund D, Van Bakel ABV, Dec GW, Lee F, Oren R, Ewald G, Kaiser P, Bourge RC for the Cardiac Transplant Research Database. Malignancy and death from malignancy after heart transplantation. Amulticenter time related risk analysis. *Journal of Heart and Lung Transplantation* 2002;21(1):55

Yancy CW, Kaiser P, DiMaio JM, Drazner MH, Dries D, Meyer DM, Ring WS. Improved outcomes in patients awaiting heart transplantation: making the case that status 2 patients should not undergo transplantation. *Journal of Heart and Lung Transplantation* 2002;21(1):69

Ring WS, DiMaio JM, Jessen ME, Kaiser PA, Meyer DM, Moncrief CL, Wait MA, Hamilton TT, Hutcheson KA, Karandikar M, Baldwin BJ, Boehrer JD, Horn VP, **Yancy CW**. Steroid withdrawal improves late survival after heart transplantation; 10 year results. *Journal of Heart and Lung Transplantation* 2002;21(1):167

Drazner MH, Thompson B, Rosenberg PB, Kaiser PA, Boehrer JD, Baldwin BJ, Dries DL, **Yancy CW**. Comparison of impedance cardiography with invasive hemodynamic measurements in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy. *The American Journal of Cardiology* April 15, 2002;89:993-995.

Wu AH, Ballantyne CM, Short BC, Zhao XQ, Bourge RC, Radovancevic B, Torre-Amione G, **Yancy CW**, Young JB, O'Brien KD. Statin use is associated with improved outcomes independent of lipid levels in heart transplant recipients. *American Heart Association Scientific Sessions 2002*. Chicago, IL.

JA Franciosa, AL Taylor, JN Cohn, **CW Yancy**, S Ziesche, A Olukotun, E Ofili, K Ferdinand, J Loscalzo, M Worcel for the A-HeFT Investigators. African-American Heart Failure Trial (A-HeFT): Rationale, Design, and Methodology. *Journal of Cardiac Failure* Vol. 8;3:128-135.

CM Ballantyne, BC Short, X Zhao, RC Bourge, B Radovancevic, G Torre-Amione, **CW Yancy**, JB Young, KD O'Brien, A Wu. Statin use is associated with improved outcomes independent of lipid levels in heart transplant recipients. *American Heart Association Scientific Sessions 2002*. November 2002. Chicago, IL.

Clyde W. Yancy and Mark H. Strong. Contemporary management of heart failure 2002: a review of the new american college of cardiology/american heart association guidelines. *Cardiology Special Edition* Vol. 8;2:22-27.

II. MANUSCRIPTS

Watenpaugh DE, **Yancy CW**, Buckey JC, Lane LD, Firth BG, Blomqvist CG. Effects of

fluid loading on hemodynamics, extracellular fluid movement, and atrial natriuretic peptide. (Presented at the FASEB Annual Meeting, 3/89). *Federation Proceedings*, 1989.

Lange RA, Cigarroa RG, **Yancy Jr CW**, Willard JE, Popma JJ, Sills MN, Hillis LD. Cocaine-induced coronary-artery vasoconstriction. *N Engl J Med* 1989;321:1557-62.

Levine BD, Buckey JC, Fritsch JM, **Yancy Jr CW**, Watenpaugh DE, Eckberg DL, Blomqvist CG. Physical fitness and cardiovascular regulation: orthostatic intolerance. *Circulation* 1989;80:II-291.

Levine BD, Buckey JC, Fritsch JM, **Yancy Jr CW**, Watenpaugh DE, Snell PG, Lane LD, Eckberg DL, Blomqvist CG. Physical fitness and cardiovascular regulation: mechanisms of orthostatic intolerance. *J Appl Physiol* 1991;70:112-22.

Watenpaugh DE, **Yancy CW**, Buckey JC, Lane LD, Hargens AR, Blomqvist CG. Role of atrial natriuretic peptide in systemic responses to acute isotonic volume expansion. *J Appl Physiol* 1992;73(4):1218-1226.

Jost CMT, **Yancy CW**, Ring WS. Combined thrombolytic therapy for prosthetic mitral valve thrombosis. *Annals Thoracic Surgery* 1993;55:159-61.

Jessen ME, Olivari MT, Wait MA, Meyer DM, **Yancy CW**, Ring WS. Right bundle branch block after cardiac transplantation. *Am J Cardiol* 1994;73:1009-11.

deFilippi CR, Willett DL, Brickner ME, Appleton CP, **Yancy CW**, Eichhorn EJ, Grayburn PA. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. *Am J Cardiol* 1995;75: 191-4.

Olivari MT, Jessen ME, Baldwin BJ, Horn VPH, **Yancy CW**, Ring WS, Rosenblatt RL. Triple-drug immunosuppression with steroid discontinuation by six months after cardiac transplantation. *J Heart Lung Transplant* 1995;14:127-35.

Karlsberg RP, DeWood MA, DeMaria AN, Berk MR, Lasher KP, for the **Milrinone-Dobutamine Study Group**. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. *Clin Cardiol* 1996;19:21-30.

Ballantyne CM, Bourge RC, Domalik LJ, Eisen HJ, Fishbein DP, Kubo SH, Lake KD, Radovancevic B, Taylor DO, Ventura HO, **Yancy CW**, Young JB. Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry. *Am J Cardiol* 1996;78(5):L532-5.

Smart FH, Naftel DC, Costanzo MR, Levine TB, Pelletier GB, **Yancy CW**, Hobbs RE, Kirklin JK, Bourge RC, Cardiac Transplant Research Database (CTRD) Group. Risk factors for early, cumulative, and fatal infections following cardiac transplantation: a multi-

institutional study. *J Heart Lung Transplant* 1996;15(4):329-41.

Rodeheffer RJ, Naftel DC, Stevenson LW, Porter CB, et al. **A multi-institutional study:** secular trends in cardiac transplant recipient and donor management in the United States, 1990-1994. *Circulation* 1996;94(11):2883-9.

Buckey JC, Gaffney FA, Lane LD, Levine BD, Watenpaugh DE, Wright SJ, **Yancy CW**, Meyer DM, Blomqvist CG. Central venous pressure in space. *J Appl Physiol* 1996;81(1):19-25.

Olivari MT, **Yancy CW**, Rosenblatt RL. An individualized protocol is more accurate than a standard protocol for assessing exercise capacity after cardiac transplantation. *J Heart Lung Transplant* 1996;15:1069-74.

Escobar JM, Olivari MT, Solomon MA, Baldwin BJ, Horn VPH, Ring SW, **Yancy CW**. Factors influencing exercise capacity after orthotopic cardiac transplantation. (Accepted by *Chest*)

Meler JD, Solomon MA, Steele JR, **Yancy CW Jr**, Parkey RW, and Fleckenstein JL. The MR appearance of volume overload in the lower extremities. *J Comput Assist Tomogr* 1997;21(6):969-73.

Johnson MR, Naftel DC, Hobbs RE, Kobashigawa JA, et al. **A multi-institutional study:** the incremental risk of female sex in heart transplantation – a multiinstitutional study of peripartum cardiomyopathy and pregnancy. *J Heart Lung Transplant* 1997;16(8):801–12.

Mills RM, Naftel DC, Kirklin JK, Vanbakel AB, et al. **A multi-institutional study:** heart transplant rejection with hemodynamic compromise – a multiinstitutional study of the role of endomyocardial cellular infiltrate. *J Heart Lung Transplant* 1997;16(8):813-21.

Drazner MH, Solomon MA, Thompson B, **Yancy CW**. Tailored therapy using dobutamine and nitroglycerin in advanced heart failure. *Am J Cardiol* 1999;84:941-3.

Hillert B, Remonte S, Rodgers G, **Yancy CW**. Improving patient outcomes by pooling resources. The Texas Heart Care Partnership Experience. *Am J Cardiol* 2000;85(3A Special Issue SI):43A-51A.

Yancy CW. Heart failure in african americans: a cardiovascular enigma. *J Card Fail* 2000;6(3):183-186.

Yancy CW, Ligon BW, Bottorff MB, Eichhorn EJ, Sackner-Bernstein J. Beta blockers: a new age of care for heart failure. *ICHE* March 2001:6-12.

Yancy CW, Adams Jr. KF, Eichhorn EJ, Mehra M, Pina I. Acute heart failure management: *Cardiology Review* May 2001.

Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA,

Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. *N Engl J Med* May 3, 2001;344(18):1358-1365.

Neily JB, Toto KH, Gardner EB, Rame JE, **Yancy CW**, Sheffield MA, Dries DL, Drazner MH. Potential contributing factors to noncompliance with dietary sodium restriction in patients with heart failure. *American Heart Journal* 2001;143 (1):29-33.

Leier Carl V, et al (**Yancy CW**). Nuggets, pearls, and vignettes of master heart failure clinicians. Masters of Heart Failure Series-Part 1 of 4. *Congestive Heart Failure* September/October 2001:245-249.

Leier Carl V, et al (**Yancy CW**). Nuggets, pearls, and vignettes of master heart failure clinicians. Masters of Heart Failure Series-Part 2 of 4. *Congestive Heart Failure* November/December 2001:297-308.

Leier, Carl V, et al (**Yancy CW**). Nuggets, pearls, and vignettes of master heart failure clinicians. Masters of Heart Failure Series-Part 4 of 4*-Treatment. *Congestive Heart Failure* March/April 2002:98-124.

Yancy, CW. The role of race in heart failure therapy. *Current Cardiology Reports* May 2002;4(3):218-225.

Smart, Frank M. and **Yancy, Clyde W**. Treatment of acute decompensated heart failure in patients chronically treated with beta-blockers. *Cardiology Exploration: Management and Treatment Strategies in Late-Stage Heart Failure*; The Cleveland Clinic Foundation. Volume 6. Monograph based on Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. *International Journal of Cardiology* December 2001;81(2-3):141-149.

CW Yancy. Special clinical considerations of beta-blocker treatment. *Reviews in Cardiovascular Medicine* Supplement Issue, 2002;3(3): S27-S35.

Clyde W. Yancy, MD. Heart failure in African Americans: Unique etiology and pharmacologic treatment responses. *Journal of the National Medical Association* January 2003;95(1):1-12.

III. REVIEWS

Firth BF, **Yancy CW**. Survival in congestive heart failure: have we made a difference? *Am J Med* 1990;88:1N-3N.

Yancy CW. Severe congestive heart failure: how successful are drug and transplant therapies. *Postgrad Med* 1991;89:111-118.

Yancy CW. Clinical trials of β -blockers in heart failure: a class review. *Am J Med*

2001;110(suppl. 5A):7-10.

Yancy CW. Heart failure in blacks: etiologic and epidemiologic differences. *Curr Cardiol Rep* 2001;3(3):191-197.

.....
.....In press

.....
.....In press

IV. BOOK

Yancy CW, Firth BG. Congestive heart failure. In: Disease-A-Month. (Ed.) RC Bone. Year Book Medical Publishers, Chicago, 1988;34(8):465.

V. CD-Roms

“Building Value in Heart Failure Management.” April 20, 2001. Paris, France. Advisory Board. Amadeus Multimedia Technologies, Ltd. and Sanofi-Synthelabo, Inc.

“Improving Heart Failure Management: Concepts, Practical Experience, and Case Studies.” June 2001. “Virtual Meeting: Case Studies in Acute Heart Failure.” An interactive CD-Rom CME program. University of Minnesota Medical School. Medical Communications Media, Inc. and Sanofi-Synthelabo, Inc.

“Back to Beta-Blockers: An Evidence Approach to Treating Hypertension, CAD and CHF.” Broadcast-November 13, 2001 (Released February 14, 2002), with Richard Katz, MD, Prakash Deedwania, MD, Christopher O’Connor, MD, **Clyde Yancy, MD**. George Washington University Medical Center and AstraZeneca.

“Case Studies in Advanced Heart Failure Management.” 2001. A CD-Rom CME program. Tulane University Health Sciences Center/Oschofsner Heart and Vascular Institute. Ingenix Pharmaceutical Services and Sanofi-Synthelabo, Inc.

VI. Video

“On the Upbeat Living with Heart Failure.” A Med Ed Solutions Company. Hurd Studios. 2001; Version 2.0. Bronze Recipient of the Telly Award for Outstanding Achievement in Patient Education.

VII. Video-enhanced Teleconference

“Pathways to the Optimal Management of Advanced Congestive Heart Failure: Issues and Controversies.” Part VIII: Balancing the Care of Patients with Complex Comorbidities,

with

James B. Young, MD, Ileana L. Pina, MD and **Clyde W. Yancy, MD**. The Cleveland Clinic Foundation, MediVia and Sanofi-Synthelabo, Inc. Fall and Winter 2001.

VIII. Monographs

“Reducing the CV Risk Burden: The Role of AII Blockade.” **C. Yancy, M.D.**, Co-Chair. CME Monograph, *Cardiovascular Summit Highlights*, 7th Annual Cardiovascular Summit: Reducing the CV Risk Burden: The Role of AII Blockade; Association of Black Cardiologist, Inc., Health Care Communications, Caribe Royale Resort, Lake Buena Vista, FL. January 2002.

IX. Book Chapters

Braumwald E (ed). Heart Disease, A Textbook of Cardiovascular Medicine. “Cardiovascular Disease in Ethnic Minorities.” **C. Yancy**. Date of submission May 2003.

Rutherford JD (ed.). Cardiology Core Curriculum. “Heart failure and cardiac transplantation”. **C. Yancy**. British Medical Journal Publishing Group. London. 2003.

X. Web-based Patient Education Tools

Chair, American Heart Association, HeartProfilers®, Heart Failure; National Spokesperson, American Heart Association HeartProfilers® [**Yancy C**. “**Online Program Aids Heart Patients and Their Doctors**”. **Cardiology Patient Page**. in *Circulation* Vol. 106 No. 18, October 29, 2002, 2299-2300.]

2002/Yancy/utsw/curriculum vitae12-02